GlassScriptPhysician profile
Jon Prescott
NPI 1437141207
$1,863.12
in general payments reported to CMS, 2019-2025
22 companies · $218 in 2025
The $218 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $166 · 2021: $193 · 2022: $351 · 2023: $202 · 2024: $283 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $702.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $459.94 | 2019-2025 | Spaceoar Vue System - 10ml |
| Bioprotect Medical, INC. | $171.17 | 2024-2025 | Bioprotect Balloon Implant System |
| Bayer Healthcare Pharmaceuticals INC. | $171.12 | 2020-2025 | |
| Blue Earth Diagnostics | $170.02 | 2020-2024 | |
| Varian Medical Systems, INC. | $138.26 | 2019 | |
| Cardinal Health INC | $105.00 | 2025 | |
| Myovant Sciences INC. | $101.35 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $101.11 | 2019 | |
| Janssen Biotech, INC. | $80.07 | 2021-2022 | |
| Isoray, INC | $63.60 | 2023 | Brachytherapy Source |
| Teleflex LLC | $45.14 | 2024-2025 | Barrigel |
| Astellas Pharma US INC | $41.17 | 2020-2021 | |
| Myriad Genetic Laboratories, INC. | $40.63 | 2021 | |
| Palette Life Sciences, INC. | $39.54 | 2022 | |
| Sumitomo Pharma America, INC. | $29.10 | 2024-2025 | Orgovyx |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $25.88 | 2022 | |
| Novartis Pharmaceuticals Corporation | $24.64 | 2024 | |
| Verity Pharmaceuticals INC. | $15.85 | 2023 | Trelstar |
| Astrazeneca Pharmaceuticals LP | $13.81 | 2024 | Lynparza |
| Progenics Pharmaceuticals, INC. | $13.18 | 2024 | |
| Tolmar Pharmaceuticals, INC. | $12.54 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$456,243.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Prescott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.